WO1998011064A1 - Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-2-substituted ethyl-2-amines - Google Patents
Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-2-substituted ethyl-2-amines Download PDFInfo
- Publication number
- WO1998011064A1 WO1998011064A1 PCT/US1997/015729 US9715729W WO9811064A1 WO 1998011064 A1 WO1998011064 A1 WO 1998011064A1 US 9715729 W US9715729 W US 9715729W WO 9811064 A1 WO9811064 A1 WO 9811064A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- compound
- reacting
- formula
- substituted aryl
- Prior art date
Links
- 0 CCC(*)N(*)I Chemical compound CCC(*)N(*)I 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/38—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reaction of ammonia or amines with sulfonic acids, or with esters, anhydrides, or halides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D203/22—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
- C07D203/24—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- This invention is directed to methods for stereospecifically preparing [(1 -optionally substituted aryl)- or ( 1-optionally substituted heteroaryl)]-2-substituted ethyl-2-amines, having chirality at the 2-position.
- the invention is directed also to intermediates to the substituted ethyl-2-amines.
- the substituted ethyl-2-amines, and intermediate compounds thereto, are useful as intermediates in the synthesis of cardiovascular agents, including antihypertensive agents, anti- ischemic agents, cardioprotective agents which ameliorate ischemic injury or myocardial infarcl size consequent to myocardial ischemia, and antilipolytic agents which reduce plasma lipid levels, serum triglyceride levels, and plasma cholesterol levels.
- the substituted ethyl-2-amines are useful as intermediates in the preparation of antihypertensive and anti-ische ic heterocyclyl adenosine derivatives and analogues as disclosed in U.S. Patent 5,364.862. They are useful also in the preparation of N 9 -cyclopentyl-substituted adenine derivatives reported to be adenosine receptor ligands, and useful in cardiovascular conditions such as hypertension, thrombosis and atherosclerosis, and also in central nervous system conditions comprising psychotic conditions such as schizophrenia, and convulsive disorders such as epilepsy, as disclosed in U.S. Patent 4.954,504. They are useful also in the preparation of N-6 and 5'-N substituted carboxamidoadenosine derivatives which have beneficial cardiovascular and antihypertensive activity as reported in U.S. Patent 5,310,731.
- the present invention is directed to methods for stereospecifically preparing [(1 -optionally substituted aryl)- or (1-optionally substituted heteroaryI)l-2-substituted ethyl-2-amines, having chirality at the 2-posi ⁇ on.
- Aryl means phenyl or naphthyl.
- Optionally substituted aryl means an aryl group which be substituted with one or more aryl group substituents.
- aryl group substituents include alkyl, alkoxy, amino, aryl, heteroaryl, trihalomethyl, nitro, carboxy, carboalkoxy, carboxyalkyl, cyano, alkyla ino, halo, hydroxy, hydroxyalkyl, mercaptyl, alkyJmercaptyl, or carbamoyl.
- Preferred aryl group substituents include halo, hydroxy, alkyl, aryl, alkoxy, trihalomethyl, cyano, nitro, and alkyl mercaptyl.
- Heteroaryl means about a 4 to about a 10 membered aromatic ring structure in which one or more of the atoms in the ring is an element other than carbon, e.g.. N, O or S.
- heteroaryl groups include pyridyl, pyridazinyl, pyrimidinyl, isoquinolinyl, quinolinyl, quinazolinyl, imidazolyl, pyrrolyl, furanyl, thienyl, thiazolyl, and benzothiazolyl.
- a preferred heteroaryl group is thienyl.
- Optionally substituted heteroaryl means that the heteroaryl group may be substituted by one or more aryl group substituents.
- heteroaryl group substituents include alkoxy, alkylamino, aryl, carbalkoxy, carbamoyl, cyano, halo, heteroaryl. trihalomethyl, hydroxy, mercaptyl, alkylmercaptyl or nitro.
- Preferred heteroaryl group substituents include halo, hydroxy, alkyl, aryl, alkoxy. trihalomethyl. cyano. nitro. and alkylmercaptyl.
- Halogen means chlorine (chloro, chloride), fluorine (fluoro, fluoride), bromine (bromo, bromide) or iodine (iodo, iodide).
- alky means a saturated aliphatic hydrocarbon group which may be straight or branched and having about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups may be straight or branched and have about 1 to about 10 carbon atoms in the chain.
- Lower alkyl means an alkyl group which may be straight or branched having about 1 to about 6 carbon atoms, such as methyl, ethyl, propyl or tert-butyl. Branched means that a lower alkyl group is attached to a linear alkyl chain.
- Aralkyl means an alkyl group substituted by an aryl group.
- Optionally substituted aralkyl means that the aryl group of the aralkyl group may be substituted with one or more aryl group substituents.
- Heteroaralkyl means an alkyl group substituted by a heteroaryl group.
- Optionally substituted heteroaralkyl means that the heteroaryl group or the heteroaralkyl group may be substituted with one or more aryl group substituents.
- Electrodeophilic scavenger means an agent that can have a promoting effect on acidolytic cleavage reactions, for example, as described by Yaji a et al.. Chem. Pharm. Bull. 26 (12) 3752- 3757 ( 1978), Kiso et al., Chem. Pharm. Bull. 28 (2) 673-676 (1980), and Kitagawa et al.. Chem. Pharm. BulL 2S (3) 926-931 ( 1980).
- An embodiment according to the invention is directed to a reaction of a 2-amino-2- substituted ethyl alcohol with a sulfonyl halide or anhydride, preferably in the presence of an aprotic organic solvent.
- Aprotic organic solvents which are suitable for the reaction include aprotic organic ethers, aromatic hydrocarbons, heteroaro atic hydrocarbons, aliphatic hydrocarbons, and aprotic organic amides. More particularly, examples of suitable aprotic organic solvents include diethyl ether, tert-butyl methyl ether, isopropyl methyl ether, diisopropyl ether, tetrahydrofuran, tetrahydropyran, and dioxan. In a special embodiment of methods according to the invention, the preferred aprotic organic solvent is tert-butyl methyl ether.
- the reaction with the sulfonyl halide or anhydride takes place preferably at a temperature range from about 25°C to about 90°C; more preferably from about 25°C to about 40°C.
- Suitable sulfonyl halides and anhydrides include phenyl-, tol-4-yl-, 2,4,6-trimethyIphenyl-, 2,4-dimethylphenyl-, 4-methoxyphenyl-, 4-nitrophenyl-, 4-bromophenyl-, naphth-1-yl-, naphth-2- yl-, and trifluoromethyl- sulfonyl chloride and anhydride.
- a preferred sulfonyl chloride is p-toluenesulfonyl chloride (i.e., tol-4-yl sulfonyl chloride).
- the reaction of the 2-amino-2 -substituted ethyl alcohol with the sulfonyl halide or anhydride takes place in the presence of a base.
- Bases which are suitable for the reaction include aqueous alkali metal hydroxides, aqueous alkali metal carbonates, and aprotic organic amines.
- suitable alkali metal hydroxides include sodium hydroxide, potassium hydroxide, and lithium hydroxide
- suitable alkali metal carbonates include potassium carbonate, sodium carbonate, and cesium carbonate
- suitable aprotic organic amines include triethylamine, diisopropyl ethyl amine, N-methylmorpholine, and pyridine.
- a preferred base is aqueous sodium hydroxide. Another embodiment according to the invention is directed to the reaction of the
- the lithium salt formed in the reaction is isolated as a solid.
- Organolithium compounds may exist as tetramers, hexamers, and higher aggregates in hydrocarbon and ether solvents, as described, for example, by Carey, F.A., and Sundberg, Richard J., Advanced Organic Chemistry, Plenum Press, New York (2d ed. 1984), and Fraenkel et al., J. Am. Chem. Soc. 102, 3345 (1980). Formation by methods according to the invention of such aggregates of the lithium salts, and the aggregates so-formed are contemplated by and included in the invention.
- the reaction to form lithium salt takes place preferably in an aprotic organic solvent.
- Aprotic organic solvents which are suitable for the reaction include aprotic organic ethers, aliphatic hydrocarbons, and aromatic hydrocarbons.
- a preferred aprotic organic solvent is an aprotic organic ether and, more particularly, tert- butyl methyl ether.
- the formation of the lithium salt takes place preferably at about -80°C to about 50°C; more preferably at about -40°C to about 50°C.
- Yet another embodiment according to the invention is directed to the treatment of the lithium salt of an [(N-optionally substituted aryl)- or (N-trihalomethyl)sulfonylj-l- [(optionally substituted aryl)- or (optionally substituted heteroaryl)]-2-substituted alkyl-2-amine having chirality at the 2- position with one or more strong acids in the presence of an electrophilic scavenger.
- This treatment takes place preferably at a temperature range of about 45°C to about reflux.
- Strong acids which are suitable for the treatment include methanesulfonic acid, trifluoroacetic acid, trifluoromethanesulfonic acid, trichloromefhane sulfonic acid, trichloroacetic acid, sulfuric acid, hydrochloric acid, hydrobromic acid, and phosphoric acid.
- the treatment takes place preferably in a mixture of strong acids; more preferably in a mixture of methanesulfonic acid and trifluoroacetic acid.
- Electrophilic scavengers which are suitable for the treatment include anisole, thioanisole, diphenyldisulfide, phenylbenzylsulfide, trimethoxybenzenc, m-cresol, and 1,2-ethanediol.
- a preferred electrophilic scavenger is thioanisole.
- a preferred embodiment according to the invention is a method for preparing a compound of Formula I,
- R is optionally substituted aryl, or optionally substituted heteroaryl; and R, is optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, comprising reacting a compound of Formula II
- R' is halo or OSO 2 R 2 ;
- R 2 is optionally substituted aryl, or trihalomethyl, in the presence of a base to form an aziridine compound of Formula IV.
- a further preferred embodiment of the present invention is the method of preparing a compound of Formula I wherein R, is optionally substituted heteroaryl; more preferably R, is 3- chlorothien-2-yl.
- Another further preferred embodiment of the invention is the method for preparing the compound of Formula I wherein R 3 is alkyl; more preferably R, is ethyl.
- Another preferred embodiment according to the invention is a method for preparing a compound of Formula I, comprising reacting the aziridine of Formula IV with a compound of formula Li-R, to form a lithium compound of Formula V,
- Another preferred embodiment according to the invention is a method for preparing a compound of Formula I, comprising treating the lithium compound of Formula V with a strong acid or mixture of strong acids in the presence of an electrophilic scavenger.
- the present invention is directed also to intermediates to [(1 -optionally substituted aryl)- or (1-optionally substituted heteroaryl)]-2-substituted ethyl-2-amines.
- a compound embodiment according to the invention is the [(N-arylsulfonyl)- or (N- trihalomethylsulfonyI)]-2-substituted aziridine having chirality at the 2-position, formed by the reaction of the of the 2-amino-2-substituted ethyl alcohol with the sulfonyl halide or anhydride according to the method of the invention.
- a preferred embodiment of said aziridine is the compound of Formula IV.
- a special embodiment of said aziridine includes 1-p-toluenesulfonyl- 2(R)-ethylaziridine.
- Another compound embodiment according invention is the lithium salt of an [(N-optionally substituted aryl)- or (N-trihalomethyl)sulfonyl]-l- Koptionally substituted aryl)- or (optionally substituted heteroaryl)]-2-substituted alkyl-2-amine having chirality at the 2-position formed by the reaction of the aziridine with an [(optionally substituted aryl)- or (optionally substituted heteroaryl)] lithium compound according to the method of the invention.
- a preferred embodiment of this lithium salt is the compound of Formula V.
- a special embodiment of the lithium salt includes is (R)- l-(3-chlorothien-2-yl)-2-butyltoluenesulfonamide lithium salt.
- the mixture is stirred for about 30 minutes at 40°C, and water (900 mL) is added while cooling the mixture to 25°C.
- the layers are separated and the organic layer washed sequentially with water (150 g) and 25% aqueous sodium chloride solution (300 g).
- Toluene (450 g) is added to the organic layer, and the mixture distilled under reduced pressure, maintaining the temperature of the mixture at or below 45°C, until the water content of the mixture is below about 0.1%.
- the resulting solution is used, without further treatment, for the preparation described in Example 2.
- 6M aqueous sodium hydroxide solution (820 mL) is then added portionwise, with stirring, maintaining the reaction temperature below 60°C.
- the layers are separated and the organic phase is washed with water until the pH of the wash is 9, then brine.
- the organic solution is cooled to 18°C and toluene (200 mL) is added followed concentrated hydrochloric acid (42 mL).
- the resulting slurry is distilled at about 47°C at 180 mm Hg to azeotropically remove water. After about 200 mL of toluene/water had been removed the mixture is cooled to 40°C, allowed to come to atmospheric pressure, then cooled to 15°C over a 1 hour period.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL97331933A PL331933A1 (en) | 1996-09-12 | 1997-09-10 | Method of carrying on stereospecific synthesis of chiral compounds of 1-aryl- and 1-hetero-aryl-2-substituted ethyl-2-amines |
JP10513724A JP2001501922A (en) | 1996-09-12 | 1997-09-10 | Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-2-substituted ethyl-2-amines |
IL12881397A IL128813A0 (en) | 1996-09-12 | 1997-09-10 | Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-2-substituted ethyl-2-amines |
APAP/P/1999/001476A AP937A (en) | 1996-09-12 | 1997-09-10 | Stereospecific preparation of chiral 1-aryl-and 1-heteroaryl-2-substituted ethyl-2-amines. |
AU42562/97A AU732332B2 (en) | 1996-09-12 | 1997-09-10 | Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-2-substituted ethyl-2-amines |
BR9711466A BR9711466A (en) | 1996-09-12 | 1997-09-10 | Process for preparing stereospecifically an ethyl-2-amine ¬ (optionally substituted 1-aryl) ou- or (1-heteroaryl-2-optionally substituted) ¾-2- substituted which has chirality in the Æo- position 2 aziridine compound and lithium compound |
EA199900281A EA001364B1 (en) | 1996-09-12 | 1997-09-10 | Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-2-substituted ethyl-2-amines |
SK269-99A SK26999A3 (en) | 1996-09-12 | 1997-09-10 | Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-2- -substituted ethyl-2-amines |
EP97940882A EP0942900A4 (en) | 1996-09-12 | 1997-09-10 | Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-2-substituted ethyl-2-amines |
CA002265886A CA2265886A1 (en) | 1996-09-12 | 1997-09-10 | Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-2-substituted ethyl-2-amines |
UA99042043A UA54451C2 (en) | 1996-09-12 | 1997-10-09 | Stereospecifical synthesis of chiral 1-aryl-and 1-heteroaryl-2-substituted ethyl-2-amines |
NO991023A NO991023L (en) | 1996-09-12 | 1999-03-02 | Stereospecific preparation of chiral 1-aryl and 1-heteroaryl-2-substituted ethyl-2-amines |
US09/266,641 US6127550A (en) | 1996-09-12 | 1999-03-11 | Stereospecific preparation of chiral 1-aryl-and 1-heteroaryl-2-substituted ethyl-2-amines |
BG103259A BG103259A (en) | 1996-09-12 | 1999-03-17 | Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-substituted ehtyl-2-amines |
US09/426,403 US6433172B1 (en) | 1996-09-12 | 1999-10-25 | Steroespecific preparation of chiral 1-aryl- and 1-heteroaryl-2-substituted ethyl-2-amines |
HK00101037A HK1022296A1 (en) | 1996-09-12 | 2000-02-22 | Stereospecific preparation of chiral 1-aryl-and 1-heteroaryl-2-sustituted ethyl-2-amines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2600596P | 1996-09-12 | 1996-09-12 | |
US60/026,005 | 1996-09-12 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/266,641 Continuation US6127550A (en) | 1996-09-12 | 1999-03-11 | Stereospecific preparation of chiral 1-aryl-and 1-heteroaryl-2-substituted ethyl-2-amines |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998011064A1 true WO1998011064A1 (en) | 1998-03-19 |
Family
ID=21829300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/015729 WO1998011064A1 (en) | 1996-09-12 | 1997-09-10 | Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-2-substituted ethyl-2-amines |
Country Status (20)
Country | Link |
---|---|
US (2) | US6127550A (en) |
EP (1) | EP0942900A4 (en) |
JP (1) | JP2001501922A (en) |
KR (1) | KR100317871B1 (en) |
CN (2) | CN1112354C (en) |
AP (1) | AP937A (en) |
AU (1) | AU732332B2 (en) |
BG (1) | BG103259A (en) |
BR (1) | BR9711466A (en) |
CA (1) | CA2265886A1 (en) |
EA (1) | EA001364B1 (en) |
HK (1) | HK1022296A1 (en) |
HU (1) | HUP0000219A3 (en) |
IL (1) | IL128813A0 (en) |
NO (1) | NO991023L (en) |
OA (1) | OA10991A (en) |
PL (1) | PL331933A1 (en) |
SK (1) | SK26999A3 (en) |
UA (1) | UA54451C2 (en) |
WO (1) | WO1998011064A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429315B1 (en) | 1998-12-31 | 2002-08-06 | Aventis Pharmaceuticals Inc. | Process for preparing N6-substituted adenosine derivatives |
KR100426030B1 (en) * | 2000-07-22 | 2004-04-03 | (주) 한켐 | Chirality conversion method in lactone sugar compounds |
KR100433179B1 (en) * | 2001-11-10 | 2004-05-27 | 주식회사 삼천리제약 | Method for Producing 2-Deoxy-L-ribose |
KR100440461B1 (en) * | 2000-08-19 | 2004-07-15 | (주) 한켐 | Process for the preparation of L-ribose using 1,4-lactone |
CN100506919C (en) * | 2006-02-23 | 2009-07-01 | 中国科学院化学研究所 | Method for conducting chiral induction to non-chiral cyanine dye aggregate using human serum protein |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU225504B1 (en) * | 1997-05-13 | 2007-01-29 | Sanofi Aventis | Novel halophenyl-(2-(2-thienyl)-ethylamino)-acetonitriles and process for producing them |
US11542299B2 (en) | 2017-06-09 | 2023-01-03 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptide containing N-substituted amino acid |
JP7568510B2 (en) * | 2018-11-30 | 2024-10-16 | 中外製薬株式会社 | Method for deprotecting peptide compounds or amide compounds, method for removing resin in solid-phase reaction, and method for producing peptide compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4933470A (en) * | 1987-10-05 | 1990-06-12 | Neorx Corporation | Method of synthesis of vicinal diamines |
US5364862A (en) * | 1990-09-25 | 1994-11-15 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive and anti-ischemic properties |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3431152A (en) * | 1967-03-23 | 1969-03-04 | American Cyanamid Co | Compositions containing aromatic sulfonyl aziridine as curing agents |
-
1997
- 1997-09-10 SK SK269-99A patent/SK26999A3/en unknown
- 1997-09-10 EA EA199900281A patent/EA001364B1/en not_active IP Right Cessation
- 1997-09-10 PL PL97331933A patent/PL331933A1/en unknown
- 1997-09-10 CA CA002265886A patent/CA2265886A1/en not_active Abandoned
- 1997-09-10 IL IL12881397A patent/IL128813A0/en not_active IP Right Cessation
- 1997-09-10 EP EP97940882A patent/EP0942900A4/en not_active Withdrawn
- 1997-09-10 CN CN97197895A patent/CN1112354C/en not_active Expired - Fee Related
- 1997-09-10 AU AU42562/97A patent/AU732332B2/en not_active Ceased
- 1997-09-10 JP JP10513724A patent/JP2001501922A/en not_active Ceased
- 1997-09-10 AP APAP/P/1999/001476A patent/AP937A/en active
- 1997-09-10 HU HU0000219A patent/HUP0000219A3/en unknown
- 1997-09-10 KR KR1019997001970A patent/KR100317871B1/en not_active IP Right Cessation
- 1997-09-10 BR BR9711466A patent/BR9711466A/en active Search and Examination
- 1997-09-10 WO PCT/US1997/015729 patent/WO1998011064A1/en not_active Application Discontinuation
- 1997-10-09 UA UA99042043A patent/UA54451C2/en unknown
-
1999
- 1999-03-02 NO NO991023A patent/NO991023L/en not_active Application Discontinuation
- 1999-03-10 OA OA9900052A patent/OA10991A/en unknown
- 1999-03-11 US US09/266,641 patent/US6127550A/en not_active Expired - Fee Related
- 1999-03-17 BG BG103259A patent/BG103259A/en unknown
- 1999-10-25 US US09/426,403 patent/US6433172B1/en not_active Expired - Fee Related
-
2000
- 2000-02-22 HK HK00101037A patent/HK1022296A1/en not_active IP Right Cessation
-
2001
- 2001-12-20 CN CN01143342A patent/CN1388119A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4933470A (en) * | 1987-10-05 | 1990-06-12 | Neorx Corporation | Method of synthesis of vicinal diamines |
US5364862A (en) * | 1990-09-25 | 1994-11-15 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive and anti-ischemic properties |
Non-Patent Citations (1)
Title |
---|
See also references of EP0942900A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429315B1 (en) | 1998-12-31 | 2002-08-06 | Aventis Pharmaceuticals Inc. | Process for preparing N6-substituted adenosine derivatives |
KR100426030B1 (en) * | 2000-07-22 | 2004-04-03 | (주) 한켐 | Chirality conversion method in lactone sugar compounds |
KR100440461B1 (en) * | 2000-08-19 | 2004-07-15 | (주) 한켐 | Process for the preparation of L-ribose using 1,4-lactone |
KR100433179B1 (en) * | 2001-11-10 | 2004-05-27 | 주식회사 삼천리제약 | Method for Producing 2-Deoxy-L-ribose |
CN100506919C (en) * | 2006-02-23 | 2009-07-01 | 中国科学院化学研究所 | Method for conducting chiral induction to non-chiral cyanine dye aggregate using human serum protein |
Also Published As
Publication number | Publication date |
---|---|
AU4256297A (en) | 1998-04-02 |
UA54451C2 (en) | 2003-03-17 |
US6127550A (en) | 2000-10-03 |
HK1022296A1 (en) | 2000-08-04 |
JP2001501922A (en) | 2001-02-13 |
KR20000036007A (en) | 2000-06-26 |
BR9711466A (en) | 1999-08-24 |
OA10991A (en) | 2001-11-07 |
CN1388119A (en) | 2003-01-01 |
AU732332B2 (en) | 2001-04-12 |
BG103259A (en) | 2000-02-29 |
EA001364B1 (en) | 2001-02-26 |
AP937A (en) | 2001-02-07 |
KR100317871B1 (en) | 2002-01-18 |
SK26999A3 (en) | 1999-10-08 |
CN1230176A (en) | 1999-09-29 |
US6433172B1 (en) | 2002-08-13 |
EP0942900A4 (en) | 2004-08-04 |
CA2265886A1 (en) | 1998-03-19 |
HUP0000219A3 (en) | 2001-04-28 |
PL331933A1 (en) | 1999-08-16 |
AP9901476A0 (en) | 1999-03-31 |
NO991023D0 (en) | 1999-03-02 |
NO991023L (en) | 1999-03-02 |
HUP0000219A2 (en) | 2000-12-28 |
CN1112354C (en) | 2003-06-25 |
EP0942900A1 (en) | 1999-09-22 |
EA199900281A1 (en) | 1999-08-26 |
IL128813A0 (en) | 2000-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101379154B1 (en) | Carbonyl asymmetric alkylation | |
US6127550A (en) | Stereospecific preparation of chiral 1-aryl-and 1-heteroaryl-2-substituted ethyl-2-amines | |
JP2001504125A (en) | Method for producing cyclopropylamine | |
JP2002534430A (en) | Process for producing N6-substituted deazaadenosine derivatives | |
US6458963B1 (en) | Process for preparing eprosartan using regioselective protection of 2,4-disubstituted-imidazole intermediates | |
WO1992015562A2 (en) | Preparation of omega-substituted alkanamide | |
US5578734A (en) | Method for the preparation of S-(+)-ethodolic acid and saline derivatives | |
JP3868534B2 (en) | Process for producing sulfonamide derivatives and intermediates | |
JPH08503195A (en) | Tartronic acids, their acetalic ethers and O-esters | |
US7109352B2 (en) | Process for producing optically active amino acid derivatives | |
HU186944B (en) | Process for producing 2-oxo-5,6,7,7a-tetrahydro-4h-thieno-bracket-3,2-c-bracket closed-pyridine derivatives | |
JP2002523490A (en) | Method for producing N-protected azetidine-2-carboxylic acids (AzeOHs) | |
JP3251722B2 (en) | Method for producing N-substituted-3-piperidinol | |
US7122696B2 (en) | Processes for preparation of N-protected-β-amino alcohols and N-protected-β-amino epoxides | |
JP2003525878A (en) | Method for producing heterocyclic compound | |
JP2002540101A (en) | Synthesis of 3-amino-3-aryl propionate | |
KR20020047255A (en) | Process for preparing oxazolines from tetrahydrofurans | |
HU224967B1 (en) | Process for producing n-[5-(diphenyl-phosphinoyl-methyl)-4-(4-fluorphenyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethan sulfonamid | |
CZ72199A3 (en) | Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-2-substituted ethyl-2-amines | |
US5981757A (en) | Nizatidine preparation | |
KR100412334B1 (en) | Novel process for preparing 4-substituted-1H-pyrrole-3-carboxylic acid ester | |
EP0373950A1 (en) | Process for preparing 1,4-bridged cyclohexane carboxylic acid derivatives and their use | |
JP2002506430A (en) | Method for producing chiral 3,4-dehydroproline | |
JPH09110825A (en) | Production of alkanesulfonamide containing little ammonium impurity | |
HU224963B1 (en) | Oxazolidinone compounds and process for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97197895.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 26999 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-721 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997001970 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2265886 Country of ref document: CA Ref document number: 2265886 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/002406 Country of ref document: MX Ref document number: 09266641 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 1998 513724 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997940882 Country of ref document: EP Ref document number: 199900281 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997940882 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09426403 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997001970 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-721 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019997001970 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 163084 Country of ref document: IL |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1999-721 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997940882 Country of ref document: EP |